Background and Aims: Immune check point inhibitors (ICIs) have been developed and showed dramatic effect in some non-small cell lung cancer patients. Moreover, some retrospective studies suggested improvement of responses to chemotherapy after use of ICIs. We evaluate efficacy of salvage chemotherapy after exposure to ICIs.
Methods: Eligible patients were adults with NSCLC who received ICIs (Nivolumab or Pembrolizumab) as second or later line therapy, then received single-agent salvage chemotherapy from January 2016 to April 2018. Clinical data were retrospectively analyzed.
Results: 26 patients were eligible. Patients mean age were 68. 20 were males vs 6 female. 14 were adeno, 11 squamous, and 1 NOS. 20 patients received Nivolumab, 6 patients were Pembrolizumab. 14 patients received ICIs as 2nd line therapy, 6 patients as 3rd line, 6 patients as 4th or later line. As for salvage chemotherapy, tegafuf/ gimeracil/oteracil (61.5%), DOC+ RAM(15.3%), DOC (7.7%), nab-PTX (3.8%), GEM (3.8%), CPT-11(3.8%) and VNR (3.8%) were used. Over all response rate (ORR) was 11.50%, Disease control rate (DCR) was 57.7%. Median progression free survival (PFS) was 3 months. Grade 1 interstitial lung disease was observed at 1 patient.
Conclusion:
Although our data include heavily treated patients who received ICIs as third or later line, ORR/DCR and PFS were comparable to historical data of second line chemotherapy. ICIs might improve efficacy of salvage chemotherapy. Background and Aims: Around 10-15% EGFR-mutated non-smallcell lung cancer (NSCLC) harbour uncommon EGFR mutations. After excluding T790M and exon 20 insertion, the remaining uncommon EGFR mutations are recognized to be sensitive to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). However, the EGFR mutation pattern of NSCLC patients with activating uncommon EGFR mutation who failed first-line EGFR-TKI therapies remained unknown.
Methods: From January 2011 to July 2017, NSCLC patients with EGFR mutation other than exon 19 deletion and L858R in National Taiwan University Hospital, National Taiwan University Hospital Yun-Lin Branch, and Far Eastern Memorial Hospital were included. The patients with de novo T790M or exon 20 insertion were excluded. The EGFR mutation data were recorded and analyzed in patients who received a second EGFR mutation test on disease progression after first-line EGFRTKIs therapies.
Results: The EGFR mutation data of NSCLC patients (n = 1984, National Taiwan University Hospital 1490 patients; National Taiwan University Hospital Yun-Lin Branch 91 patients; Far Eastern Memorial Hospital 403 patients) were retrieved. A total of 162 patients had activating uncommon EGFR mutation. Among them, 17 patients received EGFR mutation tests for disease progression after first-line EGFR-TKIs therapies. Five patients (29.4%) had T790M mutation, and 4 of them were obtained via liquid biopsy. Five patients (29.4%) lost their initial uncommon EGFR mutations. One patient (5.9%) had EGFR mutation shifted from E709V to L858R. Six patients (35.3%) remained their initial uncommon mutations. One patient (5.9%) had transformed into small-cell lung cancer but retaining the same EGFR mutation (S768I and L858R).
The proportion of acquired T790M in patients with activating uncommon EGFR mutation who failed first-line EGFR-TKIs may be relatively lower as compared to that reported in the previous literatures.
Further large-scaled studies for validation are warranted. et al., 2013) , and its staging factors are not included in the merger of diabetes. However, studies have shown that combined diabetes can increase the local recurrence rate (Varlotto et al., 2012) . The study is designed to investigate the role of diabetes in lung cancer invasion and prognosis.
Methods: Patients with first diagnosed non-small cell lung cancer and without a second primary cancer were recruited from April 2015 to May 2016. There were 109 patients were diagnosed with diabetes (the diabetes group) and 335 patients without diabetes. All patients were followed up for 2 years. The outcome evaluation was independently by the clinical stage. The Kaplan-Meier method was used to compare survival curves for patients with and without diabetes. The Cox proportional hazards model was used to estimate hazard ratios for the association between diabetes, other prognostic factors and patient survival.
Results: The baseline characters of these patients showed no significant difference beside BMI. The median follow-up was 23 months (range, 3-36 months). Compared with those who with normal glucose and insulin level, patients with diabetes not only had a shorter period of progression free survival but also had a higher risk of all-cause mortality.
Conclusion: For our results diabetes was confirmed to be an independent factor of the risk of non-small cell lung cancer which was considered to associated with the risks of progression and prognosis. A further discover the underlying mechanisms may provide a new approach to cancer treatment. 
